Large biotechs doing better than big drugmakers, report finds

04/19/2013 | BioPharm International

Big biotech firms have beaten major drugmakers since 2010 in terms of sales growth, income, research investment and market capitalization, better placing them to deal with a changing market, according to a report from Burrill & Co. Big biotech's market cap grew 57%, to $260.6 billion, from Jan. 1, 2010, to Dec. 31, 2012, compared with a 17% hike, to $1.257 billion, for major drugmakers. "The big jump in the value of Big Biotech companies is not just a matter of investor speculation," G. Steven Burrill said. "These companies have had significant clinical and market successes that have driven their values higher."

View Full Article in:

BioPharm International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID